PTP Accounts Production v24.1.4.33 SC180362 director 1.12.23 30.11.24 30.11.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC1803622023-11-30SC1803622024-11-30SC1803622023-12-012024-11-30SC1803622022-11-30SC1803622022-12-012023-11-30SC1803622023-11-30SC180362ns15:Scotland2023-12-012024-11-30SC180362ns14:PoundSterling2023-12-012024-11-30SC180362ns10:Director12023-12-012024-11-30SC180362ns10:PrivateLimitedCompanyLtd2023-12-012024-11-30SC180362ns10:SmallEntities2023-12-012024-11-30SC180362ns10:AuditExemptWithAccountantsReport2023-12-012024-11-30SC180362ns10:SmallCompaniesRegimeForDirectorsReport2023-12-012024-11-30SC180362ns10:SmallCompaniesRegimeForAccounts2023-12-012024-11-30SC180362ns10:FullAccounts2023-12-012024-11-30SC180362ns10:OrdinaryShareClass12023-12-012024-11-30SC180362ns10:CompanySecretary12023-12-012024-11-30SC180362ns10:RegisteredOffice2023-12-012024-11-30SC180362ns5:CurrentFinancialInstruments2024-11-30SC180362ns5:CurrentFinancialInstruments2023-11-30SC180362ns5:ShareCapital2024-11-30SC180362ns5:ShareCapital2023-11-30SC180362ns5:RetainedEarningsAccumulatedLosses2024-11-30SC180362ns5:RetainedEarningsAccumulatedLosses2023-11-30SC180362ns5:MotorVehicles2023-12-012024-11-30SC180362ns5:ComputerEquipment2023-12-012024-11-30SC180362ns5:MotorVehicles2023-11-30SC180362ns5:ComputerEquipment2023-11-30SC180362ns5:MotorVehicles2024-11-30SC180362ns5:ComputerEquipment2024-11-30SC180362ns5:MotorVehicles2023-11-30SC180362ns5:ComputerEquipment2023-11-30SC180362ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-11-30SC180362ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-11-30SC180362ns10:OrdinaryShareClass12024-11-30
REGISTERED NUMBER: SC180362 (Scotland)















Unaudited Financial Statements for the Year Ended 30 November 2024

for

Biocom Limited

Biocom Limited (Registered number: SC180362)






Contents of the Financial Statements
for the Year Ended 30 November 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Chartered Accountants' Report 9

Biocom Limited

Company Information
for the Year Ended 30 November 2024







DIRECTOR: CK Keir





SECRETARY: Mrs E Keir





REGISTERED OFFICE: 6 Lomond Crescent
Bridge Of Weir
Renfrewshire
PA11 3HJ





REGISTERED NUMBER: SC180362 (Scotland)





ACCOUNTANTS: GMH Chartered Accountants
Pavilion 3, Suite 2
St James Business Park
Paisley
Renfrewshire
PA3 3BB

Biocom Limited (Registered number: SC180362)

Balance Sheet
30 November 2024

30.11.24 30.11.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 29,326 39,117

CURRENT ASSETS
Stocks 5 46,581 50,921
Debtors 6 10,101 7,926
Cash at bank 106,084 112,489
162,766 171,336
CREDITORS
Amounts falling due within one year 7 39,550 14,615
NET CURRENT ASSETS 123,216 156,721
TOTAL ASSETS LESS CURRENT LIABILITIES 152,542 195,838

PROVISIONS FOR LIABILITIES 5,322 7,359
NET ASSETS 147,220 188,479

CAPITAL AND RESERVES
Called up share capital 8 100 100
Retained earnings 147,120 188,379
SHAREHOLDERS' FUNDS 147,220 188,479

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Biocom Limited (Registered number: SC180362)

Balance Sheet - continued
30 November 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 16 June 2025 and were signed by:





CK Keir - Director


Biocom Limited (Registered number: SC180362)

Notes to the Financial Statements
for the Year Ended 30 November 2024

1. STATUTORY INFORMATION

Biocom Limited is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

Significant judgements and estimates
In the application of the company's accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer [usually on dispatch of the goods], the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that is probable will be recovered.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Motor vehicles - 25% on reducing balance
Computer equipment - 25% on cost

Biocom Limited (Registered number: SC180362)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

2. ACCOUNTING POLICIES - continued

Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit and loss.

Financial instruments
The company has elected to apply the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Instruments Issues" of FRS 102 to all its financial instruments.

Financial instruments are recognised in he company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intension to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised costs using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the asset of the company after deducting all of its liabilities.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised costs, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.


Biocom Limited (Registered number: SC180362)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of stock or fixed asset.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

Biocom Limited (Registered number: SC180362)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

4. TANGIBLE FIXED ASSETS
Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 December 2023 68,270 6,047 74,317
Additions - 375 375
Disposals - (944 ) (944 )
At 30 November 2024 68,270 5,478 73,748
DEPRECIATION
At 1 December 2023 29,868 5,332 35,200
Charge for year 9,601 565 10,166
Eliminated on disposal - (944 ) (944 )
At 30 November 2024 39,469 4,953 44,422
NET BOOK VALUE
At 30 November 2024 28,801 525 29,326
At 30 November 2023 38,402 715 39,117

5. STOCKS
30.11.24 30.11.23
£    £   
Finished goods 46,581 50,921

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.11.24 30.11.23
£    £   
Trade debtors 9,501 7,669
Other debtors 600 257
10,101 7,926

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.11.24 30.11.23
£    £   
Trade creditors 6,696 5,497
Tax - 118
Social security and other taxes 200 706
VAT 8,172 219
Directors' current accounts 22,592 5,693
Accruals and deferred income 1,890 2,382
39,550 14,615

Biocom Limited (Registered number: SC180362)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.11.24 30.11.23
value: £    £   
100 Ordinary £1 100 100

9. RELATED PARTY DISCLOSURES

During the year the director, Mr C Keir operated a loan account. As at the balance sheet date the loan account position was £22,592 due from the company (2023: £5,693).

10. ULTIMATE CONTROLLING PARTY

The controlling party is CK Keir.

Chartered Accountants' Report to the Director
on the Unaudited Financial Statements of
Biocom Limited

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Biocom Limited for the year ended 30 November 2024 which comprise the Statement of Income and Retained Earnings, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of ICAS, we are subject to its ethical and other professional requirements which are detailed at http://www.icas.com/accountspreparationguidance.

This report is made solely to the director of Biocom Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Biocom Limited and state those matters that we have agreed to state to the director of Biocom Limited in this report in accordance with the requirements of ICAS as detailed at http://www.icas.com/accountspreparationguidance. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its director for our work or for this report.

It is your duty to ensure that Biocom Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Biocom Limited. You consider that Biocom Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Biocom Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






GMH Chartered Accountants
Pavilion 3, Suite 2
St James Business Park
Paisley
Renfrewshire
PA3 3BB


17 June 2025